SCHOTT Pharma AG & Co. KGaA

Healthcare · EUR · XETRA

1SXPT212

Price

€17.98

+2.98%

Cap

€2.25B

Earnings

—

30d Trend

+21.0%

1SXP

Loading chart data...

0 days · % change from startPowered by Brain47

VolatilityModerate

31% annualised over 90 days

BRAIN47 SIGNAL

MODERATE

Risk Level62

Quality68

Momentum18

Technical58

Fundamentals55

Raw weighted: 48×Macro 0.99 (−1%)=48

RISK

62/100

90d Volatility

31.0%Moderate

ATR %

3.1%High daily moves

Max Drawdown (1Y)

-56.3%Volatile

QUALITY

68/100

ROE (avg)

17.1%Good

Piotroski F-Score

5/9Average

Margin Stability

CV 3.0%Very stable

Accruals

-2.1%Cash earnings

Interest Coverage

9.3xAdequate

MOMENTUM

18/100

12-1M Momentum

-58.0%Strong downtrend

6-1M Momentum

-27.6%Negative

1M Return

+22.8%Strong recent gains

Relative Strength

+0.7% vs sectorIn-line

TECHNICAL

58/100

RSI (14)

78.5Overbought

Price vs SMA200

+5.1%Bullish trend

MACD

+0.12Bullish momentum

Bollinger Band

103%Near upper band

SMA Cross

Golden CrossGolden Cross

Trend Quality (KER)

0.650Clean trend

FUNDAMENTALS

55/100

EV/EBIT

11.9Cheap

P/FCF

64.0Expensive

P/S

2.3Fair

Shareholder Yield

1.1%Low

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months ★74

3-12 months58

1-5+ years49

5-10 day swing — momentum continuation

BRAIN47'S ASSESSMENT

I rate SCHOTT Pharma AG & Co. KGaA at 48/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 68/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.

PAST PERFORMANCE

1 MONTH

+22.8%

3 MONTHS

+21.7%

12 MONTHS

-35.2%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

5-10 day swing — momentum continuation. Quality (68) and Technical (58) are the primary strengths. I note that momentum is the weakest area at 18/100 — this warrants monitoring. Historical volatility is moderate at 31%. I classify this as a speculative position — risk characteristics and asymmetric payoff potential define the opportunity.

speculativeScore: 48/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.